Valuation : Design Therapeutics, Inc.

Market Cap 940M 809M 762M 694M 1.3B 89.44B 1.3B 9.03B 3.49B 45.57B 3.53B 3.45B 144B P/E 2026 *
-11x
P/E 2027 * -9.38x
Enterprise Value 964M 829M 781M 712M 1.33B 91.71B 1.34B 9.26B 3.58B 46.72B 3.62B 3.54B 148B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Design Therapeutics, Inc.

1 day-1.38%
1 week-3.28%
Current month-0.46%
1 month+7.36%
3 months+42.37%
6 months+44.84%
Current year+60.13%
1 week 14.71
Extreme 14.71
15.49
1 month 14.02
Extreme 14.02
16.12
Current year 8.23
Extreme 8.23
17.25
1 year 5.28
Extreme 5.28
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 25/08/2023
Chief Tech/Sci/R&D Officer - 01/06/2021
Chief Operating Officer 46 01/01/2021
Director TitleAgeSince
Chairman 56 18/12/2017
Director/Board Member 71 01/07/2019
Director/Board Member 49 01/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/03/26 Free

Director

67,500 0.1185%
02/01/26 Free

Chief Executive Officer

750,000 1.3166%
02/01/26 Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%-3.28%+126.20%+466.79% 940M
-3.24%-7.78%-5.35%+11.20% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
-0.37%-2.53%+10.91%+30.93% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.09%-2.92%+76.17%+150.67% 26.79B
Weighted average by Cap. -1.02%-3.04%+85.56%+134.32%

Financials

2026 *2027 *
Net sales - -
Net income -86.04M -74.04M -69.72M -63.52M -119M -8.19B -119M -826M -319M -4.17B -323M -316M -13.21B -115M -98.96M -93.18M -84.9M -159M -10.94B -159M -1.1B -427M -5.57B -432M -422M -17.66B
Net Debt 23.81M 20.49M 19.29M 17.58M 32.89M 2.27B 33.02M 229M 88.38M 1.15B 89.41M 87.47M 3.66B -295M -254M -239M -218M -408M -28.08B -409M -2.83B -1.1B -14.31B -1.11B -1.08B -45.32B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
09/09/26 $15.02 -1.38% 821,136
08/09/26 $15.23 +0.59% 775,062
04/09/26 $15.14 +0.73% 256,617
03/09/26 $15.03 -3.22% 376,169
02/09/26 $15.53 +2.58% 1,003,357
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.02USD
Average target price
21.00USD
Spread / Average Target
+39.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!